US-based biotechnology company Moderna and artificial intelligence research firm OpenAI have expanded their ongoing collaboration to unlock the potential of AI in healthcare.
Moderna and OpenAI initiated their collaboration in early 2023, with the launch of Moderna’s variant of ChatGPT, dubbed mChat, which was internally built on OpenAI’s API.
The collaboration enabled more than 80% internal adoption, which boosted an AI culture that allowed the deployment of ChatGPT Enterprise, along with its enhanced capabilities.
The enhanced capabilities include advanced analytics, image generation and GPTs, which are now embedded across Moderna’s legal, research, manufacturing, and commercial functions.
In addition, the GPTs are purpose-built as assistants to work alongside Moderna’s employees, extending their roles through personalised support.
While the AI tools serve as an extension to its team, Moderna is enabled to achieve its goal of delivering the highest impact to people through mRNA medicines.
Moderna CEO Stéphane Bancel said: “Just as the introduction of the personal computer in the 1980s changed the way we work and live, AI is on a path to completely transform our everyday lives – and OpenAI is helping to lead the way.
“Both our companies have shared values and are research-driven organisations pushing the boundaries of technology to drive transformation.
“Moderna has an ambitious plan to launch multiple products over the next few years, and collaborations with companies like OpenAI are critical to our ability to scale and maximise our impact on patients.”
Moderna said that it has leveraged the power of machine learning since its beginnings.
In the few months since adopting ChatGPT Enterprise, Moderna has deployed more than 750 GPTs across the company to help drive automation and productivity.
The company’s Dose ID GPT uses ChatGPT Enterprise’s Advanced Data Analytics feature to further evaluate the optimal vaccine dose selected by the clinical study team.
Dose ID offers a rationale, references its sources, and generates informative charts illustrating the key findings, by applying standard dose selection criteria and principles.
Moderna said that the tool provides a detailed review, augmented with AI input while prioritising safety and optimising the vaccine dose profile before further development in late-stage trials.
OpenAI CEO Sam Altman said: “Moderna is leading the way by empowering all of its employees to use AI to tackle complex problems. We look forward to continuing to collaborate with Moderna to bring a new generation of medicines to patients in need.”
